Investigation Report on China Pranoprofen Market, 2010-2019
|出版商||China Research and Intelligence||商品編碼||336270|
|出版日期||內容資訊||英文 20 Pages
|Pranoprofen的中國市場分析 Investigation Report on China Pranoprofen Market, 2010-2019|
|出版日期: 2015年07月24日||內容資訊: 英文 20 Pages||
Pranoprofen是千壽製藥 (日本) 開發作眼藥用的抗發炎劑，中國在1999年認證。近幾年，中國的Pranoprofen市場急速成長，2013年為6404萬人民幣的市場規模，2014年擴大到7439萬人民幣 (增加16.2％)，2010∼2014年的年複合成長率(CAGR) 達到38.7％。隨著在生活、職場雙方電腦的普及，眼科疾病患者增加，成為Pranoprofen市場成長的原因之一。
According to the 2013 Health Statistical Bulletin, outpatients totaled 62.8312 million in China in 2013. As computer pervades into work and life, eye disease cases grow by millions each year, which leads to the expansion of ophthalmic drug market.
Originally discovered by Welfide (Mitsubishi Tanabe Pharma Corporation formerly known as Yoshitomi Pharmaceutical Industries, Ltd) as an inflammatory drug, pranoprofen was later developed into eye drop by Senju Pharmaceutical Co., Ltd under the trade name of pranopulin for the treatment of inflammation of outer eye or anterior segment of the eye like blepharitis, conjunctivitis and keratitis. In 1999, pranoprofen eye drop was approved by CFDA to enter the Chinese market for clinical use, followed by product from Shandong Haishan Pharmaceutical Co., Ltd and Guangzhou Kangqiao Hanpu Pharmaceutical Co., Ltd in 2009 and product of in 2013.
Pranoprofen develops fast after entering China, sales value rising from CNY 64.04 million in 2013 to CNY 74.39 million in 2014 with a year-on-year growth of 16.2% and CAGR during the period of 2010-2014 reaching 38.7%. As computer pervades into work and life, the incidence of eye disease keeps rising, which leads to the vast demand for pranoprofen in China. Currently, pranoprofen in the Chinese market mainly come from the following three enterprises: Senju Pharmaceutical Co., Ltd, Shandong Haishan Pharmaceutical Co., Ltd and Guangzhou Kangqiao Hanpu Pharmaceutical Co., Ltd, among which Senju Pharmaceutical Co.,Ltd had the largest market share of 89.38% which dropped from 90.59% in 2013 due to Shandong Haishan Pharmaceutical Co., Ltd and Guangzhou Kangqiao Hanpu Pharmaceutical Co., Ltd's entering into the market with sales reaching CNY 66.49 million in 2014. Domestic drug is expected to occupy an increasingly large share in the next few years.